cours de bourse
14/08/2009 - 11:07:23|49.66 EUR 0.42 %
Information document available as of today as part of the proposed cross-border merger through the acquisition of Stallergenes SA by Ares Allergy Holdco Ltd.
Positive performance in all geographic regions
Significant growth in the...
STG320 is the first house dust mite immunotherapy tablet ever to obtain a...
Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world.
Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.